A Research Study to Investigate How Well the Medicine CagriSema Lowers High Blood Pressure in People Living With High Blood Pressure and Obesity
NCT07919405, Phase 3, Not yet recruiting, Novo Nordisk A/S
Trial 10
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | A Research Study to Investigate How Well the Medicine CagriSema Lowers High Blood Pressure in People Living With High Blood Pressure and Obesity | ClinicalTrials.gov |
| NCT number | NCT07919405 | ClinicalTrials.gov |
| Status | Not yet recruiting | ClinicalTrials.gov |
| Phases | Phase 3 | ClinicalTrials.gov |
| Enrollment | 1,408 participants, estimated | ClinicalTrials.gov |
| Lead sponsor | Novo Nordisk A/S | ClinicalTrials.gov |
| Conditions | Hypertension, Obesity | ClinicalTrials.gov |
| Interventions | CagriSema, Semaglutide, Cagrilintide, Placebo | ClinicalTrials.gov |
| First posted | 2026-11-05 | ClinicalTrials.gov |
| Last updated | 2026-11-05 | ClinicalTrials.gov |
Registered outcomes 16
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | CagriSema versus Placebo : Change in in-office systolic blood pressure (SBP) | From baseline (week 0) to week 32 | Measured in millimeters of mercury (mmHg). | ClinicalTrials.gov |
| Secondary | CagriSema versus Semaglutide and Cagrilintide : Change in in-office systolic blood pressure | From baseline (week 0) to week 32 | Measured in mmHg. | ClinicalTrials.gov |
| Secondary | Change in Home blood pressure monitoring (HBPM) -based systolic blood pressure | From baseline (week 0) to week 32 | Measured in mmHg. | ClinicalTrials.gov |
| Secondary | Number of participants who achieve a target goal of in-office systolic blood pressure lesser than or equal to (≤) 130 mmHg | At Week 32 | Measured as Count of participants. | ClinicalTrials.gov |
| Secondary | Number of participants who achieve American College of Cardiology and the American Heart Association (ACC/AHA) guidelines based blood pressure targets lesser than (<) 130/80 mmHg | At Week 32 | Measured as Count of participants. | ClinicalTrials.gov |
| Secondary | Change in body weight (%) | From baseline (week 0) to week 32 | Measured in percentage (%). | ClinicalTrials.gov |
| Secondary | Change in body weight (Kg) | From baseline (week 0) to week 32 | Measured in Kilograms (kg). | ClinicalTrials.gov |
| Secondary | Change in waist circumference | From baseline (week 0) to week 32 | Measured in centimetre (cm). | ClinicalTrials.gov |
| Secondary | Change in ACC/AHA 10-year atherosclerotic cardiovascular disease (ASCVD) risk score | From baseline (week 0) to week 32 | Measured in percentage of risk. ACC/AHA risk estimator calculates 10 year risk of ASCVD using a formula which includes age, sex, race, total cholesterol, high density lipoprotein (HDL) cholesterol, systolic blood pressure, blood pressure medication use, diabetes status, smoking status; minimum score 0, maximum score 100 where higher score indicates higher risk of 10-year risk of ASCVD. | ClinicalTrials.gov |
| Secondary | Ratio to baseline of lipids: Total cholesterol | From baseline (week 0) to week 32 | Measured in Ratio. | ClinicalTrials.gov |
| Secondary | Ratio to baseline of lipids: HDL cholesterol | From baseline (week 0) to week 32 | Measured in Ratio. | ClinicalTrials.gov |
| Secondary | Ratio to baseline of lipids: Low Density Lipoprotein (LDL) cholesterol | From baseline (week 0) to week 32 | Measured in Ratio. | ClinicalTrials.gov |
| Secondary | Ratio to baseline of lipids: Very Low Density Lipoprotein (VLDL) cholesterol | From baseline (week 0) to week 32 | Measured in Ratio. | ClinicalTrials.gov |
| Secondary | Ratio to baseline of lipids: Non-HDL cholesterol | From baseline (week 0) to week 32 | Measured in Ratio. | ClinicalTrials.gov |
| Secondary | Ratio to baseline of lipids: Triglycerides | From baseline (week 0) to week 32 | Measured in Ratio. | ClinicalTrials.gov |
| Secondary | Ratio to baseline of high-sensitivity C-reactive protein (hsCRP) | From baseline (week 0) to week 32 | Measured in Ratio. | ClinicalTrials.gov |
Outcomes 0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|
Results by group 0
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|
Participant flow 0
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|
Adverse events 0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|
Adverse event totals 0
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|
Papers 0
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as | Source |
|---|
Grants 0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|
Trial comparisons 0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|
Tests 0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|
Source 5
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.4.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
| NIH clinical studies file | 2026-11-13 | ClinicalTrials.gov |
Release trials-2026-11-12-0.4.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)